CDK4 and breast carcinoma: Compared with the population in the global part of the study13, more patients in the Chinese cohort had previously received chemotherapy for advanced breast cancer (29.9% versus 18.2%), and fewer had received CDK4/6 inhibitors for advanced breast cancer (37.3% versus 69.1%).